




ASO Visual Abstract: Metastasectomy or Stereotactic Body Radiation Therapy With or Without Systemic Therapy for Oligometastatic Esophagogastric Cancer

Tiuri E. Kroese, MD^{1,2} , George S. Buijs, MD^{1,2}, Matthijs D. L. Burger, BSc^{1,2}, Jelle P. Ruurda, MD, PhD¹, Stella Mook, MD, PhD², Lodewijk A. A. Brosens, MD, PhD³, Peter S. N. van Rossum, MD, PhD², and Richard van Hillegersberg, MD, PhD¹

¹Department of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; ²Department of Radiation Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; ³Department of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

Patients with esophagogastric cancer and synchronous or metachronous oligometastatic disease (OMD) who underwent local treatment or systemic therapy were included in this single-center retrospective cohort study (<https://doi.org/10.1245/s10434-022-11541-0>). OMD was defined as 1 organ with 3 or fewer lesions or 1 extra-regional lymph node station. Overall survival (OS) was determined after OMD detection. Treatment for OMD was


categorized into local treatment, local plus systemic therapy, or systemic therapy. The primary tumor was considered controlled after resection or chemoradiotherapy. Local plus systemic therapy for oligometastatic esophagogastric cancer was independently associated with improved OS and better OS compared with either systemic therapy or local treatment.

Tiuri E. Kroese, George S. Buijs shared first author.

© The Author(s) 2022

Published Online: 2 April 2022

R. van Hillegersberg, MD, PhD
e-mail: R.vanHillegersberg@umcutrecht.nl



DATA-SHARING STATEMENT All data generated and analyzed during this study are included in this published article (and its supplementary information files).

DISCLOSURE There are no conflict of interest.

OPEN ACCESS This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate

if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.